Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Transplant Cell Ther. 2021 Jun 18;27(9):770.e1–770.e7. doi: 10.1016/j.jtct.2021.06.016

Table 3-.

Transplant outcomes

Variable Chemo-mobilized Cohort N=117 Matched cohort N=117 P value
Days to neutrophil engraftment, median (range) 16 (11–26) 15 (10–29) 0.27
Days to platelets engraftment (50000), median (range) 16 (11–64) 16 (11–42) 0.22
Bacteremia, n (%) 27 (23) 22 (19) 0.52
Hospitalizations, n (%) 57 (49) 59 (51) 0.9
 Infection 20 (35) 26 (41)
 Cardiac arrhythmia 8 (14) 1 (2)
 Dehydration 17 (30) 20 (32)
 Others 12 (21) 16 (25)
Days in hospital of those hospitalized, median (IQR) 7 (5–12) 8 (5–12) 0.95
Need for RBC transfusion during ASCT, n (%) 79 (75) 55 (47) <0.001
Need for PLT transfusion during ASCT, n (%) 95 (88) 101 (86) 0.7
Neutropenic fever, n (%) 64 (58) 70 (60) 0.89
Mucositis, n (%) 39 (33) 36 (31) 0.77

n=number; IQR=interquartile range.